[1] WHO. Human papillomavirus vaccines:WHO position paper[EB/OL].(2017-05-12)[2019-04-13].https://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf ;jsessionid=F19B0E7749F9AF1A0780C74039D3B9B8?sequence=1. [2] 许雪梅. 人乳头瘤病毒及宫颈癌疫苗的研究-解读2008年诺贝尔生理学或医学奖[J].生物化学与生物物理进展,2008, 35(10):1095-1103. [3] U.S. FOOD&DRUG ADMINISTRATION. HIGHLIGHTS OF PRESCRIBING INFORMATION [EB/OL].(2018-10-05)[2019-04-13].https://www.fda.gov/media/90064/download. [4] U.S. FOOD&DRUG ADMINISTRATION. October 5,2018 Summary Basic of Regulatory Action GARDASIL 9. [EB/OL].(2018-10-05)[2019-04-13].https://www.fda.gov/media/117054/download. [5] 国家药品监督管理局.进口药品[EB/OL].(2018-04-28)[2019-04-13].http://qy1.sfda.gov.cn/datasearchcnda/face3/base.jsp?tableId=36&tableName=TABLE36&title=%E8%BF%9B%E5%8F%A3%E8%8D%AF%E5%93%81&bcId=152904858822343032639340277073. [6] Ferreira C A P, Oliveira C R N, Medeiros D S J, et al. Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials[J]. Journal of Imm-unology Research, 2017,2017:1-6. [7] Pier L .Spotlight on the 9-valent HPV vaccine[J]. Drug Design, Development and Therapy, 2016, 11:35-44. [8] 董铎, 陈易新, 孙利华. 美国疫苗不良事件报告系统[J]. 中国药物警戒, 2005, 2(4):241-243. [9] Dr Eugene P. van Puijenbroek, Diemont W L , Grootheest K V . Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions[J]. Drug Safety, 2003, 26(5):293-301. [10] Varricchio F.The Vaccine Adverse Event Reporting System[J]. Clinical Toxicology, 1998, 36(7):765-768. [11] Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System. VAERS Data Use Guide[EB/OL].(2017-10)[2019-04-13].https://vaers.hhs.gov/docs/VAERSDataUseGuide_October2017.pdf. [12] U.S. FOOD&DRUG ADMINISTRATION. Code of Federal Regulations Title 21, Volume 7 (21CFR600.80)[EB/OL].(2018-04-01)[2019-04-13].https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm. [13] 任经天, 王胜锋, 侯永芳,等. 常用药品不良反应信号检测方法比较研究[J]. 中国药物警戒, 2011,8(6):356-359. [14] Slade B A, Leidel L, Vellozzi C, et al.Postlicensure safety surveillance for quadrivalent human papillomavirus reco-mbinant vaccine[J]. Jama, 2009, 302(7):750-757. [15] 杨威. 药物警戒信号检测实践[M].天津:天津科技翻译出版有限公司,2018:137-138. [16] Evans S J W, Waller P C, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]. Pharmacoepidemiology and Drug Safety, 2001, 10(6):483-486. [17] 卜擎燕, 熊宁宁, 邹建东, 等. ICH国际医学用语词典(MedDRA):药事管理的标准医学术语集[J]. 中国临床药理学与治疗学, 2007, 12(5):586-590. [18] Findlow H, Borrow R.Interactions of conjugate vaccines and co-administered vaccines[J].Hum Vaccin Immunother. 2015, 12(1):226-230. [19] MERCK.FDA Grants Priority Review to Merck's Supplemental Biologics License Application (sBLA) for GARD-ASIL 9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases[EB/OL].(2018-06-13)[2019-04-13].https://www.mrk-newsroom.com/news-release/vaccine-news/fda-grants-priority-review-mercks-supplemental-biologics-license-applicati. [20] Committee to Review Adverse Effects of Vaccines,Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality[M/OL]. Washington (DC): National Academies Press (US), (2011-08-25) [2019-04-13].https://www.ncbi.nlm.nih.gov/books/NBK190024/. [21] Arana J E, Harrington T, Cano M, et al.Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS)[J]. Vaccine, 2018,36(13):1781-1788. [22] 王亚丽. 人乳头状瘤病毒疫苗上市后不良反应监测概况[J]. 中国药物警戒, 2017,7(14):439-442. [23] Little D T, Ward H R G. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination[J]. BMJ Case Reports, 2012-10-03. [24] Forster A, Wardle J, Stephenson J, et al.Passport to Promiscuity or Lifesaver: Press Coverage of HPV Vaccination and Risky Sexual Behavior[J]. Journal of Health Communication, 2010, 15(2):205-217. [25] Suzuki S, Hosono A.No Association between HPV Vaccine and Reported Post-Vaccination Symptoms in Japanese Young Women: Results of the Nagoya Study[J]. Papillo-mavirus Research, 2018,5:96-103. [26] D.Y. Yang,K. Bracken.Update on the new 9-valent vaccine for human papillomavirus prevention[J]. Canadian Family Physician M decin De Famille Canadien, 2016, 62(5):399-402. [27] Richardson C T, Hayden M S, Gilmore E S, et al.Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure[J]. Am J Clin Dermatol, 2018,19(1):119-126. [28] Chu Chien-Ho,Cheng Yu-Pin,Chan Jung-Yi Lisa. Alopecia Areata After Vaccination: Recurrence with Rechallenge[J]. Pediatric Dermatology, 2016, 33(3):218-219. [29] Geier D A,Geier M R .A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events[J]. Clinical Rheumatology, 2015, 34(7):1225-1231. [30] 中华口腔医学会口腔黏膜病专业委员会,中华口腔医学会中西医结合专业委员会,周刚,等. 复发性阿弗他溃疡诊疗指南(试行)[J]. 中华口腔医学杂志, 2012, 47(7):402-404. [31] Stillo M, Carrillo Santisteve P, Lopalco P L.Safety of human papillomavirus vaccines:a review[J].Expert Opin Drug Saf,2015,14(5):697-712. [32] 宋旭辉, 张日, 吕仁慧. 紧张症的研究进展及争议[J]. 中华精神科杂志, 2018(3):204-208. [33] 蔡婷, 杨羽, 王亚丽, 等. 疫苗上市后安全性主动监测模式分析[J].中国药物警戒, 2017,8(14):464-469. |